{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:38:59Z","timestamp":1777855139755,"version":"3.51.4"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002402","name":"Sun Yat-sen University","doi-asserted-by":"publisher","award":["2017010"],"award-info":[{"award-number":["2017010"]}],"id":[{"id":"10.13039\/501100002402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002402","name":"Sun Yat-sen University","doi-asserted-by":"publisher","award":["2015021"],"award-info":[{"award-number":["2015021"]}],"id":[{"id":"10.13039\/501100002402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002402","name":"Sun Yat-sen University","doi-asserted-by":"publisher","award":["201315"],"award-info":[{"award-number":["201315"]}],"id":[{"id":"10.13039\/501100002402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002402","name":"Sun Yat-sen University","doi-asserted-by":"publisher","award":["2019023"],"award-info":[{"award-number":["2019023"]}],"id":[{"id":"10.13039\/501100002402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2505800"],"award-info":[{"award-number":["2022YFC2505800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009334","name":"Pearl River S and T Nova Program of Guangzhou Municipality","doi-asserted-by":"publisher","award":["201806010135"],"award-info":[{"award-number":["201806010135"]}],"id":[{"id":"10.13039\/501100009334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["202201011561"],"award-info":[{"award-number":["202201011561"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012245","name":"Science and Technology Planning Project of Guangdong Province","doi-asserted-by":"publisher","award":["2019B020230002"],"award-info":[{"award-number":["2019B020230002"]}],"id":[{"id":"10.13039\/501100012245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272882"],"award-info":[{"award-number":["82272882"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003267"],"award-info":[{"award-number":["82003267"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073003"],"award-info":[{"award-number":["82073003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82002852"],"award-info":[{"award-number":["82002852"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272739"],"award-info":[{"award-number":["82272739"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82222050"],"award-info":[{"award-number":["82222050"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203776"],"award-info":[{"award-number":["82203776"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173287"],"award-info":[{"award-number":["82173287"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32200651"],"award-info":[{"award-number":["32200651"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203125"],"award-info":[{"award-number":["82203125"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2018B030306001"],"award-info":[{"award-number":["2018B030306001"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020732","name":"Innovative Research Team of High-level Local University in Shanghai","doi-asserted-by":"publisher","award":["SSMU-ZLCX20180500"],"award-info":[{"award-number":["SSMU-ZLCX20180500"]}],"id":[{"id":"10.13039\/100020732","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.radonc.2023.110051","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T20:54:03Z","timestamp":1703105643000},"page":"110051","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Phase I dose-escalation study of nab-paclitaxel combined with cisplatin and capecitabin as induction chemotherapy followed by concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma"],"prefix":"10.1016","volume":"191","author":[{"family":"Yu-Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8476-6286","authenticated-orcid":false,"given":"Mei-Juan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong-Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Wen","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin-Quan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Yun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Ting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Hua","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai-Lan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7632-3648","authenticated-orcid":false,"given":"Ji-Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiu-Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-Qiang","family":"Mai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan-Shan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2023.110051_b0005","doi-asserted-by":"crossref","unstructured":"Chen YP, Ismaila N. Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. 2021;39:840-59.2021. 10.1200\/jco.20.03237842.","DOI":"10.1200\/JCO.20.03237"},{"key":"10.1016\/j.radonc.2023.110051_b0010","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2020.12.007","article-title":"Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2020)","volume":"2021","author":"Bossi","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2023.110051_b0015","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial","volume":"2016","author":"Sun","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.110051_b0020","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2008.18.1545","article-title":"Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma","volume":"2009","author":"Hui","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.110051_b0025","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejca.2016.12.039","article-title":"Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial","volume":"2017","author":"Cao","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2023.110051_b0030","unstructured":"Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, et al. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. 2019;381:1124-35.2019. 10.1056\/NEJMoa1905287756."},{"key":"10.1016\/j.radonc.2023.110051_b0035","doi-asserted-by":"crossref","unstructured":"Wong KCW, Hui EP, Lo KW. Nasopharyngeal carcinoma: an evolving paradigm. 2021;18:679-95.2021. 10.1038\/s41571-021-00524-x200.","DOI":"10.1038\/s41571-021-00524-x"},{"key":"10.1016\/j.radonc.2023.110051_b0040","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJM199504133321507","article-title":"Paclitaxel (taxol)","volume":"1995","author":"Rowinsky","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2023.110051_b0045","doi-asserted-by":"crossref","unstructured":"Lee AWM, Ngan RKC, Ng WT, Tung SY, Cheng AAC, Kwong DLW, et al. NPC-0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma. 2020;126:3674-88.2020. 10.1002\/cncr.32972955.","DOI":"10.1002\/cncr.32972"},{"key":"10.1016\/j.radonc.2023.110051_b0050","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1001\/jamaoncol.2022.0122","article-title":"Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial","volume":"2022","author":"Li","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2023.110051_b0055","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jconrel.2013.05.041","article-title":"nab-Paclitaxel mechanisms of action and delivery","volume":"2013","author":"Yardley","year":"2013","journal-title":"J Control Release"},{"key":"10.1016\/j.radonc.2023.110051_b0060","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1186\/s12885-016-2517-5","article-title":"Phase I\/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab\u00ae-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma","volume":"16","author":"Huang","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2023.110051_b0065","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.oraloncology.2017.04.018","article-title":"A phase II trial of induction NAB-paclitaxel and cisplatin followed by concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma","volume":"2017","author":"Ke","year":"2017","journal-title":"Oral Oncol"},{"key":"10.1016\/j.radonc.2023.110051_b0070","first-page":"1532","article-title":"Intensity modulated radiotherapy for local-regional advanced nasopharyngeal carcinoma","volume":"2004","author":"Zhao","year":"2004944","journal-title":"Ai Zheng"},{"key":"10.1016\/j.radonc.2023.110051_b0075","doi-asserted-by":"crossref","first-page":"525","DOI":"10.5732\/cjc.013.10124","article-title":"Long-term outcome and late toxicities of simultaneous integrated boost-intensity modulated radiotherapy in pediatric and adolescent nasopharyngeal carcinoma","volume":"2013","author":"Tao","year":"2013","journal-title":"Chin J Cancer"},{"key":"10.1016\/j.radonc.2023.110051_b0080","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/107327481402100304","article-title":"Phase 1 trial design: is 3 + 3 the best?","volume":"2014","author":"Hansen","year":"2014","journal-title":"Cancer Control"},{"key":"10.1016\/j.radonc.2023.110051_b0085","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.ejca.2014.05.021","article-title":"Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx","volume":"2014","author":"Loong","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2023.110051_b0090","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/cncr.29208","volume":"2015","author":"Lee","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2023.110051_b0095","doi-asserted-by":"crossref","first-page":"17360","DOI":"10.18632\/oncotarget.14477","article-title":"Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis","author":"Zong","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.radonc.2023.110051_b0100","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/cam4.382","article-title":"Nab-paclitaxel-based compared to docetaxel-based induction chemotherapy regimens for locally advanced squamous cell carcinoma of the head and neck","volume":"2015","author":"Schell","year":"2015","journal-title":"Cancer Med"},{"key":"10.1016\/j.radonc.2023.110051_b0105","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.oraloncology.2017.07.001","article-title":"nab-Paclitaxel-based induction chemotherapy with or without cetuximab for locally advanced head and neck squamous cell carcinoma","volume":"2017","author":"Adkins","year":"2017","journal-title":"Oral Oncol"},{"key":"10.1016\/j.radonc.2023.110051_b0110","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/annonc\/mdx770","article-title":"A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006\u201302)","volume":"2018","author":"Frikha","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2023.110051_b0115","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.ijrobp.2015.01.002","article-title":"Concurrent chemo-radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: a randomized, phase 2\/3 trial in locally advanced nasopharyngeal carcinoma","volume":"2015","author":"Tan","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110051_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.oraloncology.2016.07.015","article-title":"nab-Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma","volume":"2016","author":"Adkins","year":"2016","journal-title":"Oral Oncol"},{"key":"10.1016\/j.radonc.2023.110051_b0125","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.critrevonc.2019.04.021","article-title":"Does nab-paclitaxel have a higher incidence of peripheral neuropathy than solvent-based paclitaxel? Evidence from a systematic review and meta-analysis","volume":"2019","author":"Guo","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.radonc.2023.110051_b0130","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S2468-1253(16)30219-9","article-title":"Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial","volume":"2017","author":"Shitara","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.radonc.2023.110051_b0135","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1470-2045(15)00542-2","article-title":"Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial","volume":"2016","author":"Untch","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.110051_b0140","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/jamaoncol.2017.4612","article-title":"Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2\/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial","volume":"2018","author":"Gianni","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2023.110051_b0145","doi-asserted-by":"crossref","first-page":"109699","DOI":"10.1016\/j.radonc.2023.109699","article-title":"Comparison the acute toxicity of two different induction chemotherapy schedules with cisplatin and fluorouracil in nasopharyngeal carcinoma patients","volume":"2023","author":"Zong","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.110051_b0150","doi-asserted-by":"crossref","unstructured":"Lv JW, Qi ZY, Zhou GQ, He XJ, Chen YP, Mao YP, et al. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients receiving additional induction chemotherapy. 2018;109:751-63. 10.1111\/cas.13474260.","DOI":"10.1111\/cas.13474"},{"key":"10.1016\/j.radonc.2023.110051_b0155","doi-asserted-by":"crossref","first-page":"104675","DOI":"10.1016\/j.oraloncology.2020.104675","article-title":"Individualized cumulative cisplatin dose for locoregionally-advanced nasopharyngeal carcinoma patients receiving induction chemotherapy and concurrent chemoradiotherapy","volume":"107","author":"Wen","year":"2020","journal-title":"Oral Oncol"},{"key":"10.1016\/j.radonc.2023.110051_b0160","first-page":"2679","article-title":"Exploratory Study of NPC-0501 Trial: Optimal Cisplatin Dose of Concurrent and Induction\/Adjuvant Chemotherapy for","volume":"2022","author":"Ng","year":"2022","journal-title":"Locoregionally Advanced Nasopharyngeal Carcinoma"},{"key":"10.1016\/j.radonc.2023.110051_b0165","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/annonc\/mdy249","volume":"2018","author":"Hong","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2023.110051_b0170","doi-asserted-by":"crossref","first-page":"105972","DOI":"10.1016\/j.oraloncology.2022.105972","article-title":"Plasma Epstein-Barr viral DNA load after completion of two cycles of induction chemotherapy predicts outcomes for patients with advanced-stage nasopharyngeal carcinoma","volume":"131","author":"Zong","year":"2022","journal-title":"Oral Oncol"},{"key":"10.1016\/j.radonc.2023.110051_b0175","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ijrobp.2015.08.003","article-title":"The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma","volume":"2015","author":"Liu","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110051_b0180","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(21)00075-9","article-title":"Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial","volume":"2021","author":"Lv","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.110051_b0185","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/CAD.0b013e32830f9046","article-title":"Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status","volume":"2008","author":"Desai","year":"2008","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.radonc.2023.110051_b0190","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(21)01123-5","article-title":"Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"2021","author":"Chen","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2023.110051_b0195","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1001\/jamaoncol.2022.4656","article-title":"Adjuvant Capecitabine Following Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Clinical Trial","volume":"2022","author":"Miao","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2023.110051_b0200","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(23)00163-8","article-title":"Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis","volume":"2023","author":"Petit","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.110051_b0205","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.1998.16.4.1310","article-title":"Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099","volume":"1998","author":"Al-Sarraf","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.110051_b0210","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1093\/jnci\/djq258","article-title":"Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma","volume":"2010","author":"Lee","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2023.110051_b0215","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1002\/cncr.28049","volume":"2013","author":"Chen","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2023.110051_b0220","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ejca.2010.10.026","article-title":"Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials","volume":"2011","author":"Lee","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2023.110051_b0225","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1158\/1078-0432.CCR-17-2656","article-title":"Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized Trials","volume":"2018","author":"Chen","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2023.110051_b0230","first-page":"59","article-title":"Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients","volume":"2022","author":"Blanchard","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.110051_b0235","doi-asserted-by":"crossref","first-page":"79953","DOI":"10.18632\/oncotarget.20389","article-title":"Comparing the efficacy of induction-concurrent with concurrent-adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a propensity score matching analysis","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.radonc.2023.110051_b0240","doi-asserted-by":"crossref","first-page":"104686","DOI":"10.1016\/j.oraloncology.2020.104686","article-title":"Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A propensity score-matched analysis","volume":"105","author":"Tang","year":"2020","journal-title":"Oral Oncol"},{"key":"10.1016\/j.radonc.2023.110051_b0245","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S1470-2045(00)00019-X","article-title":"Repopulation of tumour cells between cycles of chemotherapy: a neglected factor","volume":"2000","author":"Davis","year":"2000","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.110051_b0250","doi-asserted-by":"crossref","unstructured":"Chen YH, Luo SD, Wu SC, Wu CN. Clinical Characteristics and Predictive Outcomes of Recurrent Nasopharyngeal Carcinoma-A Lingering Pitfall of the Long Latency. 2022;14.2022. 10.3390\/cancers14153795965.","DOI":"10.3390\/cancers14153795"},{"key":"10.1016\/j.radonc.2023.110051_b0255","first-page":"1469","article-title":"Clinical Characteristics and Prognostic Factors of Early and Late Recurrence After Definitive Radiotherapy for Nasopharyngeal Carcinoma. Front","volume":"10","author":"Li","year":"2020","journal-title":"Oncol"},{"key":"10.1016\/j.radonc.2023.110051_b0260","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejca.2019.07.007","article-title":"Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial","volume":"2019","author":"Yang","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2023.110051_b0265","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.radonc.2017.07.020","article-title":"Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial","volume":"2018","author":"Yang","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.110051_b0270","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3109\/07357907.2012.691193","article-title":"Biological response of nasopharyngeal carcinoma to radiation therapy: a pilot study using serial 18F-FDG PET\/CT scans","volume":"2012","author":"Lin","year":"2012","journal-title":"Cancer Invest"},{"key":"10.1016\/j.radonc.2023.110051_b0275","article-title":"18F-FMISO PET-guided dose escalation with multifield optimization intensity-modulated proton therapy in nasopharyngeal carcinoma. Asia Pac","author":"Sommat","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.110051_b0280","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1093\/jnci\/94.21.1614","article-title":"Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma","volume":"2002","author":"Chan","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2023.110051_b0285","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1056\/NEJMoa032260","article-title":"Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma","volume":"2004","author":"Lin","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2023.110051_b0290","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ijrobp.2004.03.002","article-title":"Another way to estimate outcome of advanced nasopharyngeal carcinoma\u2013is concurrent chemoradiotherapy adequate?","volume":"2004","author":"Lin","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110051_b0295","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/hed.10238","article-title":"Outpatient weekly 24-hour infusional adjuvant chemotherapy of cisplatin, 5-fluorouracil, and leucovorin for high-risk nasopharyngeal carcinoma","volume":"2003","author":"Lin","year":"2003","journal-title":"Head Neck"},{"key":"10.1016\/j.radonc.2023.110051_b0300","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0360-3016(01)02781-X","article-title":"A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients","volume":"2002","author":"Chi","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.110051_b0305","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.oraloncology.2016.11.008","article-title":"Prognostic impact of adjuvant chemotherapy in high-risk nasopharyngeal carcinoma patients","volume":"2017","author":"Liu","year":"2017","journal-title":"Oral Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023093581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023093581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:20:18Z","timestamp":1777504818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814023093581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":61,"alternative-id":["S0167814023093581"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2023.110051","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I dose-escalation study of nab-paclitaxel combined with cisplatin and capecitabin as induction chemotherapy followed by concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2023.110051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110051"}}